Pathological brain ageing: Evaluation of the efficacy of a pharmacological aid

The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t₀), after 90 days (t₁), and after 180 days (t₂). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t₁ and t₂, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.